Citation Impact
Citing Papers
Characterization of MicroRNA Expression Levels and Their Biological Correlates in Human Cancer Cell Lines
2007 StandoutNobel
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
2011 Standout
Circadian oscillation of nucleotide excision repair in mammalian brain
2009 StandoutNobel
Loss of cryptochrome reduces cancer risk in p53 mutant mice
2009 StandoutNobel
Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
2000
Gastric cancer
2016 Standout
A gene expression database for the molecular pharmacology of cancer
2000 Nobel
Systematic variation in gene expression patterns in human cancer cell lines
2000 Standout
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications
2004 Standout
Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer
1990
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
2004 Standout
Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.
1997
Taxotere???5???-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells
2005
Cancer drug resistance: an evolving paradigm
2013 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity
1992
Pharmacodynamics in cancer therapy.
1990
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine
2010
Definition and classification of cancer cachexia: an international consensus
2011 Standout
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Feature selection based on mutual information criteria of max-dependency, max-relevance, and min-redundancy
2005 Standout
Regulation of nucleotide excision repair activity by transcriptional and post-transcriptional control of the XPA protein
2010 StandoutNobel
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Circadian clock control of the cellular response to DNA damage
2010 StandoutNobel
The pathobiology of mucositis
2004 Standout
Capecitabine: A review
2005
Cancer Chemotherapy in Older Adults
1997
How to calculate the dose of chemotherapy
2002
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Limited-sampling models for anticancer agents
1994
A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
2001
Chemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area
2006
Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer
1994
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Integration of EGFR inhibitors with radiochemotherapy
2006
A protein expression database for the molecular pharmacology of cancer
1997
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Prevention of head and neck cancer: Current status and future prospects
2004
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity
2005
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.
1991
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?
2002
The NCI60 human tumour cell line anticancer drug screen
2006 Standout
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis
2004
A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma
1997
Minireview Magnetically controlled targeted micro-carrier systems
1989
Gender differences in drug responses
2006
Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation.
1993
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies
2004
Model-Based Clustering, Discriminant Analysis, and Density Estimation
2002 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Upconversion Nanoparticles: Design, Nanochemistry, and Applications in Theranostics
2014 Standout
Medroxyprogesterone Acetate Elevation of Nm23-H1 Metastasis Suppressor Expression in Hormone Receptor–Negative Breast Cancer
2005
ZD1839 Modulates Paclitaxel Response in Renal Cancer by Blocking Paclitaxel-Induced Activation of the Epidermal Growth Factor Receptor–Extracellular Signal-Regulated Kinase Pathway
2004
5-Fluorouracil Incorporated into DNA Is Excised by the Smug1 DNA Glycosylase to Reduce Drug Cytotoxicity
2007 StandoutNobel
Emergence of the Epidemic Methicillin-Resistant Staphylococcus aureus Strain USA300 Coincides with Horizontal Transfer of the Arginine Catabolic Mobile Element and speG -mediated Adaptations for Survival on Skin
2013
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
2003 Standout
Policy: NIH to balance sex in cell and animal studies
2014 StandoutNature
Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation
2005
Antiviral Stilbene 1,2-Diamines Prevent Initiation of Hepatitis C Virus RNA Replication at the Outset of Infection
2011 StandoutNobel
Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity
2007
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas
2012
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
A circadian gene expression atlas in mammals: Implications for biology and medicine
2014 Standout
Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing ATP-Binding Cassette Family Protein
2005
The oral fluoropyrimidines in cancer chemotherapy.
1999
Circadian Rhythms: Mechanisms and Therapeutic Implications
2007
Control of skin cancer by the circadian rhythm
2011 StandoutNobel
Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses
2012 Standout
Relationship between systemic 5-FU passage and response in colorectal cancer patients treated with intrahepatic chemotherapy
1987
Circadian Timing in Cancer Treatments
2010
The Role of Clock Genes in Pharmacology
2010
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
2000
Circadian Clock, Cancer, and Chemotherapy
2014 StandoutNobel
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index
2013 Standout
Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results
2002
Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma
2007 Standout
Rattle-Structured Multifunctional Nanotheranostics for Synergetic Chemo-/Radiotherapy and Simultaneous Magnetic/Luminescent Dual-Mode Imaging
2013
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial
2004
Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review
2008
Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Institutional Study
2004 Standout
Dose translation from animal to human studies revisited
2007 Standout
Works of N. Renée being referenced
Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
1995
Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
1999
Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients.
1992
5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer
1989
Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil
2003
Population study of dihydropyrimidine dehydrogenase in cancer patients.
1994
Dihydropyrimidine dehydrogenase activity in cancer patients
1993
Relationship between fluorouracil systemic exposure and tumor response and patient survival.
1994
Influence of sex and age on fluorouracil clearance.
1992
Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.
1995
HPLC micromethod for simultnaeous measurement of estradiol, progesterone, androgen and glucocorticoid receptor levels. Application to breast cancer biopsies
1987
Dose Versus pharmacokinetics for predicting tolerance to 5‐day continuous infusion of 5‐FU
1988
Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase
1996
Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver
2003
Chronopharmacokinetics of Oral Tegafur and Uracil in Colorectal Cancer Patients
2007
Étude des variations circadiennes de l’activité de la dihydropyrimidine déshydrogénase (DPD) dans la muqueuse buccale chez des sujets volontaires sains
2003
Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: Pharmacokinetic evaluation
1985
Tumoral platinum concentrations in patients treated with repeated low‐dose cisplatin as a radiosensitizer
1996
Polyamine levels in normal human skin
1983
Systemic blood levels after intra-arterial administration of microencapsulated mitomycin C in cancer patients
1985
K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy
2008
Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours
1987
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
2003